GovChime
Notice ID: 24aa2d1a239f4cd7b9a767eccea783b5PresolicitationArchived

Emergent Drug Panel-Version 2 (EDP-V2) Kit

Archived on September 29, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
11:00 AM EDT
Posted
September 9, 2026
Notice type
Presolicitation
NAICS
541715: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC OFFICE OF ACQUISITION SERVICES
Place of performance
Atlanta, Georgia, 30341
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
000HCNBG-2026-99823
Notice ID
24aa2d1a239f4cd7b9a767eccea783b5

Description

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price contract to Cayman Chemical Company, Inc. for the design, manufacture, distribution, and associated laboratory support services for the Emergent Drug Panel-Version 2 (EDP-V2) Kit, a new product line addition within CDC's Traceable Opioid Material (TOM®) Kit program, and continued distribution, product support, and data collection services for existing Emergent Drug Panel (EDP) Kit products. The anticipated period of performance is 09/30/2026 through 09/29/2027. The requirement will include four option years for design and manufacture of additional kits as well as continuous distribution. The Government intends to solicit and negotiate with only one source under the authority of FAR 12.102(a).

CDC requires a contractor to:

1. Design and manufacture EDP-V2 kits containing reference materials for emerging synthetic opioids and related drugs of concern (including synthetic opioids, novel benzodiazepines, synthetic cathinones, and related novel psychoactive substances) contributing to the opioid epidemic, meeting or exceeding Current Good Manufacturing Practice (cGMP) standards;

2. Obtain and maintain a DEA exemption/registration status enabling distribution of controlled and non-controlled reference materials to CDC-approved laboratories;

3. Distribute EDP-V2 kits and all other existing EDP Kit product lines to approved laboratories nationally;

4. Provide ongoing product support, customer service, and technical assistance to recipient laboratories for all EDP Kit products;

5. Collect, maintain, and report kit distribution and use-case metrics to CDC in accordance with OMB-approved data collection requirements; and

6. Conduct stability testing on existing EDP Kit materials nearing expiration to determine potential for shelf-life extension.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received prior to the date and time below will be considered by the government. NOTE: Interested vendors must clearly provide evidence of their capability to be considered. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to the Contracting Officer at xur0@cdc.gov by 11:00AM (ET) on 09/14/2026.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Taylor Wellman

Documents

No documents available.

Lifecycle

  1. 3
    Version 3PresolicitationArchivedCurrent

    Emergent Drug Panel-Version 2 (EDP-V2) Kit

    Notice 24aa2d1a239f4cd7b9a767eccea783b5 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

000HCNBG-2026-99823

Archive Date

Sep 29, 2026

Office Address

ATLANTA, GA, 30333